Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07387952

The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation:a Pilot Study

Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18 to 70.
  • Diagnostic criteria: Functional constipation (FC) in accordance with Rome IV criteria, which should meet the following conditions:
  • Symptom requirements: The following at least 2 items should occur in ≥25% of bowel movements: a. Straining during defecation; b. Hard stool (Bristol Stool Classification score 1-2); c. Feeling of incomplete evacuation; d. Rectal obstruction sensation; e. Need for finger assistance during defecation; f. Spontaneous bowel movements <3 times per week.
  • It is rare to have loose stools without laxatives.
  • Exclusion of irritable bowel syndrome (IBS): IBS diagnosis criteria not meeting Rome IV.
  • Disease course requirements: Symptoms persist for at least 6 months and meet the above criteria within the last 3 months.
  • Traditional treatment methods (dietary intervention, at least two laxatives or probiotics) are ineffective.

Exclusion criteria

  • Pregnancy or lactation.
  • Unable to take the intervention product or complete the examination as required.
  • Language expression disorder or mental illness.
  • Physical examination showed severe liver and kidney dysfunction.
  • Acute gastrointestinal disease within 4 weeks.
  • Constipation caused by surgery in the past 4 weeks.
  • History or abnormal examination: cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease, hypothyroidism, mental illness, stroke, heart disease, cirrhosis, renal failure, hematopoietic system diseases, organic bowel disease suggested by colonoscopy or imaging.
  • Participation in other clinical trials within 3 months prior to enrollment.
  • Other health problems are not suitable for participation in the study.

Treatment and study plan

FMT

Procedure

In this group, colonoscopy is performed and a colostomy is placed in the ileocecal region. Bacterial infusion is performed for 3 days with 100ml graft per day. Within 30 minutes after receiving the microbiota transplantation, take the high dietary fiber preparation and dissolve it in water according to the instructions. Blood, stool, and colonoscopy-derived mucosal samples are collected before and after FMT and Researchers conduct follow-ups.

Other names: FMT with nutritional intervention

Primary outcomes

  1. Frequency of Defecation (Spontaneous Bowel Movements)

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

    The number of Spontaneous Bowel Movements (SBM) per week recorded by the participant in a diary.

  2. Stool Consistency Assessed by Bristol Stool Form Scale (BSFS)

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

    Stool consistency is evaluated using the Bristol Stool Form Scale. The scale ranges from Type 1 (Separate hard lumps) to Type 7 (Liquid consistency). Type 1 and 2 indicate constipation, while Type 3 and 4 are considered normal. Higher scores indicate looser stool consistency.

  3. Severity of Defecation Straining

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

    Patient-reported assessment of the effort required to defecate. Participants rate their straining severity on a scale (e.g., from 0 to 3, where 0 represents no straining and 3 represents severe straining). Higher scores indicate worse symptoms.

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: From baseline through Week 24

    Number of participants with adverse events. Assessment includes monitoring for specific gastrointestinal symptoms (e.g., aggravation of diarrhea, abdominal discomfort/bloating) and systemic infections (e.g., secondary intestinal infection, bacteremia). Safety is assessed via telephone and offline visits.

  2. Change in Gut Microbiota Composition Assessed by Metagenomic Sequencing

    Time frame: Baseline, Weeks 2, 4, 8, 12, 18, and 24

    Fecal samples are collected to analyze the changes in the gut microbiota structure. Analysis includes the relative abundance of bacterial species and diversity indices (e.g., Shannon index) using Metastats analysis to compare pre- and post-treatment compositions.

Study contacts

Contact information is provided by the study sponsor or research team.

Pengguang Yan

CONTACT

[email protected]

+8618810309887

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 4, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.